| Trial ID: | L7193 |
| Source ID: | NCT06333977
|
| Associated Drug: |
Lc542019
|
| Title: |
A Study of LC542019 in Healthy Subjects and Subjects With T2DM
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Healthy|Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: LC542019|DRUG: Placebo
|
| Outcome Measures: |
Primary: Incidence, severity of adverse events, up to 4 weeks | Secondary: Maximum Concentration (Cmax) in Plasma, up to 4 weeks|Renal Clearance (CLR) in urine, up to 2 weeks | Other: Cardiodynamic evaluation, concentration-QTc analysis, up to 4 weeks|Fasting Plasma Glucose, up to 4 weeks|HbA1c, up to 4 weeks
|
| Sponsor/Collaborators: |
Sponsor: LG Chem
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
100
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2022-03-25
|
| Completion Date: |
2023-12-14
|
| Results First Posted: |
|
| Last Update Posted: |
2024-03-27
|
| Locations: |
PPD Development, LP (PPD Clinical Research Unit, Las Vegas), Las Vegas, Nevada, 89113, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT06333977
|
